Amgen Inc. ($AMGN) Stock Forecast: Up 5.2% Today

What is Amgen Inc.?

Amgen (NASDAQ: AMGN) operates in the biotechnology sector and is recognized for its advancements in various therapeutic areas such as oncology and metabolic diseases. The company witnessed a significant upward movement in its stock price today.

Why is Amgen Inc. going up?

AMGN stock is up 5.2% on Jul 2, 2025 14:00

• Bemarituzumab, Amgen's gastric cancer drug, demonstrated enhanced survival rates in Phase 3 trials for advanced gastric cancer patients, likely bolstering investor trust in the company's pipeline and future revenue opportunities.
• The progress of MariTide, a monthly treatment for obesity in late-stage trials, signals Amgen's strategic move into the obesity market, attracting investor attention and optimism.
• The commencement of a Phase 3 study by VKTX on an obesity candidate might suggest growing competition in the obesity treatment sector, yet Amgen's established reputation and robust pipeline could help it maintain a competitive position.
• The prevailing positive market sentiment and Amgen's +1.03% stock price rise may indicate investor confidence in the company's innovative drug pipeline and its potential for future expansion and growth.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects - Amgen ( NASDAQ:AMGN )

Bemarituzumab plus chemo improved survival in FGFR2b+ advanced gastric cancer patients. Most common side effects included visual issues, anemia, neutropenia, and nausea. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.

https://www.benzinga.com/news/health-care/25/06/46175014/amgens-gastric-cancer-drug-improves-survival-in-phase-3-notes-ocular-side-effects

Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

https://www.zacks.com/stock/news/2556095/amgen-looks-to-take-share-of-booming-obesity-space-will-it-succeed

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

https://www.zacks.com/stock/news/2554915/vktx-initiates-phase-3-study-on-obesity-candidate-vk2735

Amgen ( AMGN ) Stock Moves 1.03%: What You Should Know

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

https://www.zacks.com/stock/news/2554126/amgen-amgn-stock-moves-103-what-you-should-know

Trending Today

Extra Space Storage Inc ($EXR) Stock Forecast: Down 9.6% Today

DexCom Inc. ($DXCM) Stock Forecast: Down 8.0% Today

eBay Inc. ($EBAY) Stock Forecast: Up 17.2% Today

Datadog Inc. ($DDOG) Stock Forecast: Down 5.4% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 7.3% Today

BorgWarner Inc. ($BWA) Stock Forecast: Up 5.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Down 5.9% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 11.2% Today

Ethena ($ENA) Crypto Forecast: Up 13.3% Today

MGM Resorts International ($MGM) Stock Forecast: Down 5.7% Today

Amgen Inc. Price History

15.10.2024 - AMGN Stock was down 5.2%

• Concerns over the impact of Amgen's experimental weight loss injection, MariTide, on bone density appeared to have a notable effect on investor sentiment.
• Despite a surge in options trading and optimistic sentiments from well-funded investors, the safety concerns linked to MariTide outweighed the positive market sentiment.
• Comments from Jim Cramer on the stock's performance and potential advantages for competitor Eli Lilly notably contributed to the downward pressure on Amgen's shares.
• Overall, the market's response to the safety concerns surrounding MariTide eclipsed any positive developments, resulting in the decline of Amgen's stock price.

20.11.2024 - AMGN Stock was up 5.4%

• Despite a slight decrease in the most recent trading session, the overall bullish movement of Amgen's stock indicates strong investor confidence in the company.
• The -0.21% shift may be attributed to minor profit-taking or market fluctuations rather than any significant negative news impacting the company.
• Investors continue to show interest in Amgen due to its robust pipeline of biopharmaceutical products and potential for future growth in the healthcare industry.
• The positive sentiment towards Amgen aligns with the broader market optimism towards biotech companies, driving the stock's bullish movement.

17.03.2025 - AMGN Stock was down 6.3%

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

05.01.2025 - AMGN Stock was up 5.4%

• The strong bullish movement of Amgen (AMGN) today is attributed to an impressive Q4 earnings report that surpassed expectations in both earnings and sales, indicating the company's strong financial position and growth potential.
• Despite the FDA's decision to place a clinical hold on Amgen's obesity candidate, AMG 513, which initially raised concerns among investors, the overall positive earnings results overshadowed this development.
• The high bullish sentiment among investors, evident from options trading data, further boosted the stock's upward trend, reflecting a positive outlook on Amgen's future.
• Despite the regulatory setback with AMG 513, Amgen's robust performance in Q4 and the optimistic market sentiment suggest that the company is well-positioned for continued growth within the biotech sector.

05.01.2025 - AMGN Stock was up 6.6%

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

26.10.2024 - AMGN Stock was down 11.9%

• The release of data from the Phase 2 study of MariTide showing weight loss of up to 20% in obese patients might have raised concerns about the drug's market potential, leading to a bearish sentiment.
• Despite the bullish options activity on Amgen, the overall market reaction to the obesity drug data seems to have overshadowed this positive sentiment.
• The bearish movement could also be influenced by investor uncertainty surrounding the competitive profile of other companies in the biopharmaceutical sector, as seen with Silence Therapeutics' stock decline despite positive study results.

24.05.2025 - AMGN Stock was down 5.8%

• AMGN's stock price closed at $272.44, representing a significant -5.84% decrease compared to the previous day.
• The market response was influenced by the mixed outcomes of Part 1 of its Phase 2 study of MariTide, causing uncertainty among investors and resulting in downward pressure on the stock.
• Options trading activities indicate a prevailing bearish sentiment, with a majority of traders leaning towards pessimistic positions, exacerbating the selling pressure on AMGN's shares.
• Despite the current downward trend, some investors may view the decline in AMGN's stock price as an opportunity to potentially profit from the company's history of developing cutting-edge therapies in the long run.

05.01.2025 - AMGN Stock was up 5.1%

• Amgen (AMGN) experienced a strong bullish movement.
• The positive sentiment may stem from expectations of surpassing Q4 earnings estimates.
• Investors are optimistic about Amgen's performance for the quarter ending December 2024, contributing to the bullish trend.
• The market movement indicates faith in Amgen's potential to deliver robust financial outcomes, sparking investor enthusiasm for the stock.

09.03.2025 - AMGN Stock was down 5.7%

• The approval of Amgen's Uplizna for new rare autoimmune disease indications by the FDA was positive news for the company.
• Despite the positive developments with Uplizna, the stock saw a bearish trend, possibly due to profit-taking after recent spikes in the past year.
• The market's overall volatility and uncertainty may have contributed to the stock's decline despite the positive news.
• Investors might be cautious about the company's future performance, leading to a sell-off despite the overall market taking a dip.

02.06.2025 - AMGN Stock was up 5.2%

• Bemarituzumab, Amgen's gastric cancer drug, demonstrated enhanced survival rates in Phase 3 trials for advanced gastric cancer patients, likely bolstering investor trust in the company's pipeline and future revenue opportunities.
• The progress of MariTide, a monthly treatment for obesity in late-stage trials, signals Amgen's strategic move into the obesity market, attracting investor attention and optimism.
• The commencement of a Phase 3 study by VKTX on an obesity candidate might suggest growing competition in the obesity treatment sector, yet Amgen's established reputation and robust pipeline could help it maintain a competitive position.
• The prevailing positive market sentiment and Amgen's +1.03% stock price rise may indicate investor confidence in the company's innovative drug pipeline and its potential for future expansion and growth.

04.03.2025 - AMGN Stock was down 5.0%

• The FDA approval of Uplizna as the first drug for a chronic immune-mediated fibroinflammatory disorder should have been a positive catalyst for Amgen, but the bearish movement suggests otherwise.
• Despite positive clinical data and market resilience, the stock experienced a significant plunge, possibly due to profit-taking or broader market uncertainties.
• The bearish sentiment from deep-pocketed investors, as indicated by options trading, might have contributed to the downward pressure on Amgen's stock price.
• The mixed signals from the market, including a recent rise amidst a general market dip and a slight decrease in P/E ratio, could have added to the overall confusion and led to the bearish movement in AMGN today.

23.05.2025 - AMGN Stock was down 5.4%

• Today's bearish movement in AMGN may have been driven by market sentiment reflected through options trading, where a majority of traders displayed bearish tendencies.
• Noteworthy bearish actions by financial giants on Amgen might have caused apprehension among investors, prompting a sell-off of the stock.
• The analysis of options history revealing a higher percentage of bearish trades could have intensified the negative sentiment surrounding Amgen and contributed to today's significant bearish movement in the stock.